NAUT · Full Picture

Nautilus Biotechnology, Inc. — the full picture

Earnings window · 2026-04-07 to 2026-07-25 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Equity Offering Programs · Equity issuance & dilutionPriority 58
    qualitative only
    Under a Sales Agreement entered in February 2024 with Cowen and Company, LLC (TD Cowen), Nautilus may offer and sell up to $125.0 million of shares of common stock from time to time through an at-the-market offering program, and TD Cowen is entitled to up to 3.0% of gross proceeds as compensation.
  2. Investing Activities and Securities · Investments & securitiesPriority 57
    +7.4% cash (realized)
    During the three months ended March 31, 2026, net cash provided by investing activities resulted from $25.8 million in proceeds from maturities of securities, partially offset by $11.1 million in purchases of securities and $0.5 million in purchases of property and equipment.
  3. Operating Expense Trends · Operating expenses (SG&A)Priority 53
    2 forward row(s)
    Nautilus expects its expenses and capital requirements will increase substantially in connection with continuing research and development, establishing service laboratory operations, building sales/marketing/distribution capabilities, setup costs for production tooling and testing, protecting intellectual property, implementing operational systems, and hiring personnel.
  4. Guidance / Outlook · Guidance & outlookPriority 46
    qualitative only
  5. Quarterly Results Snapshot · Revenue growth & mixPriority 45
    qualitative only
    Nautilus' net loss was $14.7 million for the three months ended March 31, 2026.
  6. Regulatory / Compliance Costs · Regulatory action & investigationsPriority 45
    qualitative only
  7. Research and Development Expense · R&D investmentPriority 45
    qualitative only
    Research and development expenses were $9,707,000 for the three months ended March 31, 2026, compared to $11,536,000 for the three months ended March 31, 2025, a decrease of $1,829,000 or 16%.
  8. Operating Cash Flow Trends · Cash flow generationPriority 44
    qualitative only
    Net cash used in operating activities was $13,100,000 for the three months ended March 31, 2026, and $13,937,000 for the three months ended March 31, 2025.
  9. Liquidity and Cash Position · Liquidity & cash positionPriority 42
    +1.2% cash (realized)
    As of the filing of this Quarterly Report on Form 10-Q, Nautilus believes its existing cash, cash equivalents, and short-term investments will enable it to fund planned operating expenses and capital expenditures through at least the next 12 months.
  10. Product Launch and Transition · Products & launchesPriority 41
    3 forward row(s)
    Nautilus expects to initiate its commercial launch in late 2026 by opening the Nautilus Voyager platform for pre-orders.
  11. Market Demand Trends · Demand, orders & backlogPriority 40
    1 forward row(s)
    Nautilus' ability to generate revenue sufficient to achieve profitability is expected to take a number of years and will depend on successful development and commercialization of the Nautilus Voyager platform.
  12. Interest Rate and Refinancing Exposure · Interest ratesPriority 39
    1 forward row(s)
    Any future debt financing Nautilus may enter could impose covenants restricting operations, including limits on liens or additional debt, dividend payments, repurchases of common stock, certain investments, and certain merger, consolidation or asset sale transactions.

Threads by pillar

Revenue & Demand Priority 59 · 3 threads

Costs & Margins Priority 73 · 6 threads

Capital & Balance Sheet Priority 78 · 5 threads

Legal, Regulatory & Policy Priority 45 · 1 thread

Guidance & Outlook Priority 46 · 1 thread

Macro & Market Conditions Priority 44 · 2 threads

Unclassified Priority 40 · 2 threads

Expected impact by metric

metricforward netforward grossrealized
cash——+8.6%
assets——+0.3%